On August 28, 2023, the Board of Directors (the ?Board?) of Eterna Therapeutics Inc. (the ?Company?) appointed Ms. Dorothy J. Clarke as a director, effective on August 28, 2023. Ms. Clarke will serve as a member of the Board until the Company?s 2024 Annual Meeting of Stockholders and until her successor is duly elected or appointed and qualified or her earlier death, resignation or removal. The Board anticipates appointing Ms. Clarke to serve on one or more committees of the Board, but at the time of filing this Current Report Form 8-K, the Board has not determined the committee(s) to which she will be appointed.

The Company will file an amendment to this Current Report on Form 8-K within four business days of the appointment of Ms. Clarke to any committee of the Board. Ms. Clarke, 58 years old, served in various roles with Johnson & Johnson (?J&J?) from April 2002 until November 2022, with the most recent position being Vice President, Health Care Compliance, Research & Development, Innovation and Business Development. Before that, Ms. Clarke served as Vice President, Health Care Compliance for the Medical Devices segment of J&J and Chief Privacy Officer of J&J. From January 2016 until December 2021, Ms. Clark served on the board of trustees of the Reformed Church of Highland Park Affordable Housing Corporation.

Ms. Clark received her bachelor?s degree in history from Wesleyan University and her Juris Doctorate from New York University School of Law. There are no arrangements or understandings between Ms. Clarke and any other person pursuant to which Ms. Clarke was appointed as a director of the Company. The Board has determined that Ms. Clarke is independent under the applicable rules of the Nasdaq Stock Market.